Table 1.

Biofilm formation and antibiotic susceptibility pattern of Pseudomonas isolates.

Isolates	Biofilm capacity	Antibiotics sensitivity testing
		Resistance phenotype	Interpretative %
			R	I	S
PS-1	++++	PRL, FEP, CDZ, IPM, AK, TOB, CN, OFX, GAT, NA, CIP, NOR, and LEV	100	0.0	0.0
PS-2	+++	PRL, FEP, CDZ, IPM, AK, TOB, OFX, GAT, NA, CIP, NOR, and LEV	92.3	7.7	0.0
PS-3	++	FEP, CDZ, and IPM	30.8	7.7	61.5
PS-4	+++	PRL, FE,P and CDZ	30.8	38.5	30.8
PS-5	+++	FEP, CDZ, IPM, and NA	30.8	38.5	30.8
PS-6	++	FEP, CDZ, IPM, and NA	30.8	7.7	61.5
PS-7	+	FEP, CDZ, IPM, and NA	30.8	7.7	61.5
PS-8	+	FEP, CDZ, IPM, and NA	30.8	0.0	69.2
PS-9	+	FEP, CDZ, IPM, and NA	38.5	15.4	46.2
PS-11	+	PRL, FEP, CDZ, IPM, and NA	38.5	15.4	46.2
PS-12	+	FEP, CDZ, IPM, and NA	30.8	7.7	61.5
PS-13	+	FEP, CDZ, IPM, and NA	30.8	7.7	61.5
PS-14	–	FEP, CDZ, IPM, and NA	30.8	7.7	61.5
PS-15	–	PRL, FEP, CDZ, IPM, AK, TOB, CN, OFX, GAT, NA, CIP, NOR, and LEV	100	0.0	0.0
PS-16	–	PRL, FEP, CDZ, IPM, AK, TOB, CN, OFX, GAT, NA, CIP, NOR, and LEV	100	0.0	0.0
PS-17	++	PRL, FEP, CDZ, IPM, AK, OFX, GAT, NA, CIP, NOR and LEV	84.6	7.7	7.7
PS-18	+	FEP, CDZ, IPM, and NA	30.8	7.7	61.5
PS-19	+++	PRL, FEP, CDZ, IPM, AK, TOB, CN, OFX, GAT, NA, CIP, NOR, and LEV	100	0.0	0.0
PS-21	+	PRL, FEP, CDZ, and IPM	38.5	7.7	53.8
PS-22	+	FEP, CDZ, and IPM	30.8	7.7	53.8

PRL, piperacillin; FEP, cefepime; CDZ, ceftazidime; IPM, imipenem; AK, amikacin; TOB, tobramycin; CN, gentamycin; OFX, ofloxacin; GAT, gatifloxacin; NA, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; LEV, levofloxacin; S, sensitive; I, intermediate; R, resistant; (−), non-biofilm producer; (+), weak biofilm producer; (++), moderate biofilm producer; (+++) and more, Strong biofilm producer isolates shown in bold letters